Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Structural Analysis of the Interaction between the Bacterial Cell Division Proteins FtsQ and FtsB.

Kureisaite-Ciziene D, Varadajan A, McLaughlin SH, Glas M, Montón Silva A, Luirink R, Mueller C, den Blaauwen T, Grossmann TN, Luirink J, Löwe J.

MBio. 2018 Sep 11;9(5). pii: e01346-18. doi: 10.1128/mBio.01346-18.

2.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.

PMID:
29808316
3.

Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.

Kebir S, Rauschenbach L, Gielen GH, Schäfer N, Tzaridis T, Scheffler B, Giordano FA, Lazaridis L, Herrlinger U, Glas M.

J Clin Neurosci. 2018 Jul;53:255-258. doi: 10.1016/j.jocn.2018.04.056. Epub 2018 May 10.

PMID:
29754968
4.

Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience.

Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, Lohmann P, Kebir S, Herrmann K, Fink GR, Langen KJ, Glas M, Galldiks N.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(9):1626-1635. doi: 10.1007/s00259-018-3992-5. Epub 2018 Mar 21.

PMID:
29564490
5.

Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial.

Giordano FA, Brehmer S, Mürle B, Welzel G, Sperk E, Keller A, Abo-Madyan Y, Scherzinger E, Clausen S, Schneider F, Herskind C, Glas M, Seiz-Rosenhagen M, Groden C, Hänggi D, Schmiedek P, Emami B, Souhami L, Petrecca K, Wenz F.

Neurosurgery. 2018 Mar 8. doi: 10.1093/neuros/nyy018. [Epub ahead of print]

PMID:
29528443
6.

11C-MET PET/MRI for detection of recurrent glioma.

Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, Hense J, Quick HH, Glas M, Herrmann K, Umutlu L, Moenninghoff C, Radbruch A, Forsting M, Schlamann M.

Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):593-601. doi: 10.1007/s00259-017-3916-9. Epub 2017 Dec 28.

PMID:
29282517
7.

Noninvasive Assessment of Intra-Abdominal Pressure Using Ultrasound-Guided Tonometry: A Proof-of-Concept Study.

Bloch A, Glas M, Kohler A, Baumann U, Jakob SM.

Shock. 2018 Dec;50(6):684-688. doi: 10.1097/SHK.0000000000001085.

PMID:
29251669
8.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

PMID:
29121274
9.

Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients.

Hattingen E, Müller A, Jurcoane A, Mädler B, Ditter P, Schild H, Herrlinger U, Glas M, Kebir S.

Oncotarget. 2017 Jun 27;8(32):53542-53551. doi: 10.18632/oncotarget.18612. eCollection 2017 Aug 8.

10.

Neuroprotection with the P53-Inhibitor Pifithrin-μ after Cardiac Arrest in a Rodent Model.

Glas M, Frick T, Springe D, Putzu A, Zuercher P, Grandgirard D, Leib SL, Jakob SM, Takala J, Haenggi M.

Shock. 2018 Feb;49(2):229-234. doi: 10.1097/SHK.0000000000000917.

11.

Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial.

Herrlinger U, Schäfer N, Fimmers R, Griesinger F, Rauch M, Kirchen H, Roth P, Glas M, Bamberg M, Martus P, Thiel E, Korfel A, Weller M.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1815-1821. doi: 10.1007/s00432-017-2423-5. Epub 2017 Apr 22.

12.

18F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor.

Kebir S, Kimmich O, Niehusmann P, Gaertner FC, Essler M, Landsberg J, Klockgether T, Simon M, Herrlinger U, Glas M.

Oncol Lett. 2016 Dec;12(6):4705-4707. doi: 10.3892/ol.2016.5234. Epub 2016 Oct 10.

13.

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.

Kebir S, Khurshid Z, Gaertner FC, Essler M, Hattingen E, Fimmers R, Scheffler B, Herrlinger U, Bundschuh RA, Glas M.

Oncotarget. 2017 Jan 31;8(5):8294-8304. doi: 10.18632/oncotarget.14166.

14.

Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.

Müller A, Jurcoane A, Kebir S, Ditter P, Schrader F, Herrlinger U, Tzaridis T, Mädler B, Schild HH, Glas M, Hattingen E.

Cancer Med. 2017 Jan;6(1):89-99. doi: 10.1002/cam4.966. Epub 2016 Nov 28.

15.

A change of colloid from hydroxyethyl starch to gelatin does not reduce rate of renal failure or mortality in surgical critical care patients: Results of a retrospective cohort study.

Albrecht FW, Glas M, Rensing H, Kindgen-Milles D, Volk T, Mathes AM.

J Crit Care. 2016 Dec;36:160-165. doi: 10.1016/j.jcrc.2016.07.005. Epub 2016 Jul 9.

PMID:
27546766
16.

Impedance aggregometric analysis of platelet function of apheresis platelet concentrates as a function of storage time.

Glas M, Bauer JV, Eichler H, Volk T.

Scand J Clin Lab Invest. 2016 Dec;76(8):664-670. Epub 2016 Oct 5.

PMID:
27701904
17.

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases.

Kebir S, Rauschenbach L, Galldiks N, Schlaak M, Hattingen E, Landsberg J, Bundschuh RA, Langen KJ, Scheffler B, Herrlinger U, Glas M.

Neuro Oncol. 2016 Oct;18(10):1462-4. doi: 10.1093/neuonc/now154. Epub 2016 Sep 2. No abstract available.

18.

Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.

Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Küpper M, Rauschenbach L, Fimmers R, Shepherd TM, Trageser D, Till A, Schäfer N, Glas M, Hillmer AM, Cichon S, Smith AA, Pietsch T, Liu Y, Reynolds BA, Yachnis A, Pincus DW, Simon M, Brüstle O, Steindler DA, Scheffler B.

Clin Cancer Res. 2017 Jan 15;23(2):562-574. doi: 10.1158/1078-0432.CCR-15-2089. Epub 2016 Aug 12.

19.

The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.

Schaub C, Schäfer N, Mack F, Stuplich M, Kebir S, Niessen M, Tzaridis T, Banat M, Vatter H, Waha A, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2016 Aug;142(8):1825-9. doi: 10.1007/s00432-016-2187-3. Epub 2016 Jun 18.

PMID:
27318492
20.

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.

J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.

PMID:
27193554
21.

Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.

Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B, Glas M.

J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21.

PMID:
27100354
22.

18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.

Kebir S, Gaertner FC, Mueller M, Nelles M, Simon M, Schäfer N, Stuplich M, Schaub C, Niessen M, Mack F, Bundschuh R, Greschus S, Essler M, Glas M, Herrlinger U.

Oncol Lett. 2016 Mar;11(3):2195-2198. Epub 2016 Feb 4.

23.

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol. 2016 May 10;34(14):1611-9. doi: 10.1200/JCO.2015.63.4691. Epub 2016 Mar 14.

PMID:
26976423
24.

Therapy of leptomeningeal metastasis in solid tumors.

Mack F, Baumert BG, Schäfer N, Hattingen E, Scheffler B, Herrlinger U, Glas M.

Cancer Treat Rev. 2016 Feb;43:83-91. doi: 10.1016/j.ctrv.2015.12.004. Epub 2015 Dec 24. Review.

PMID:
26827696
25.

Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):321-322. doi: 10.1007/s00401-015-1523-z.

PMID:
26744347
26.

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.

Kebir S, Fimmers R, Galldiks N, Schäfer N, Mack F, Schaub C, Stuplich M, Niessen M, Tzaridis T, Simon M, Stoffels G, Langen KJ, Scheffler B, Glas M, Herrlinger U.

Clin Cancer Res. 2016 May 1;22(9):2190-6. doi: 10.1158/1078-0432.CCR-15-1334. Epub 2015 Dec 16.

27.

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.

Scholz A, Harter PN, Cremer S, Yalcin BH, Gurnik S, Yamaji M, Di Tacchio M, Sommer K, Baumgarten P, Bähr O, Steinbach JP, Trojan J, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Braun C, Schittenhelm J, Frueh JT, Ullrich E, Mittelbronn M, Plate KH, Reiss Y.

EMBO Mol Med. 2016 Jan 1;8(1):39-57. doi: 10.15252/emmm.201505505.

28.

Gliomatosis cerebri: no evidence for a separate brain tumor entity.

Herrlinger U, Jones DTW, Glas M, Hattingen E, Gramatzki D, Stuplich M, Felsberg J, Bähr O, Gielen GH, Simon M, Wiewrodt D, Schabet M, Hovestadt V, Capper D, Steinbach JP, von Deimling A, Lichter P, Pfister SM, Weller M, Reifenberger G.

Acta Neuropathol. 2016 Feb;131(2):309-319. doi: 10.1007/s00401-015-1495-z. Epub 2015 Oct 22. Erratum in: Acta Neuropathol. 2016 Feb;131(2):321-2.

29.

The Soluble Periplasmic Domains of Escherichia coli Cell Division Proteins FtsQ/FtsB/FtsL Form a Trimeric Complex with Submicromolar Affinity.

Glas M, van den Berg van Saparoea HB, McLaughlin SH, Roseboom W, Liu F, Koningstein GM, Fish A, den Blaauwen T, Heck AJ, de Jong L, Bitter W, de Esch IJ, Luirink J.

J Biol Chem. 2015 Aug 28;290(35):21498-509. doi: 10.1074/jbc.M115.654756. Epub 2015 Jul 9.

30.

Melatonin or ramelteon therapy differentially affects hepatic gene expression profiles after haemorrhagic shock in rat--A microarray analysis.

Kleber A, Ruf CG, Wolf A, Fink T, Glas M, Wolf B, Volk T, Abend M, Mathes AM.

Exp Mol Pathol. 2015 Oct;99(2):189-97. doi: 10.1016/j.yexmp.2015.06.019. Epub 2015 Jun 25.

PMID:
26116814
31.

Evolutionary trends and functional anatomy of the human expanded autophagy network.

Till A, Saito R, Merkurjev D, Liu JJ, Syed GH, Kolnik M, Siddiqui A, Glas M, Scheffler B, Ideker T, Subramani S.

Autophagy. 2015;11(9):1652-67. doi: 10.1080/15548627.2015.1059558.

32.

Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.

Giessen-Jung C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Schulz C, Heinemann V, Di Gioia D, Stieber P.

Tumour Biol. 2015 Sep;36(10):7897-906. doi: 10.1007/s13277-015-3522-z. Epub 2015 May 8.

PMID:
25953265
33.

DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2.

Lopez-Bertoni H, Lal B, Li A, Caplan M, Guerrero-Cázares H, Eberhart CG, Quiñones-Hinojosa A, Glas M, Scheffler B, Laterra J, Li Y.

Oncogene. 2015 Jul 23;34(30):3994-4004. doi: 10.1038/onc.2014.334. Epub 2014 Oct 20.

34.

A novel device for target controlled administration and reflection of desflurane--the Mirus™.

Bomberg H, Glas M, Groesdonk VH, Bellgardt M, Schwarz J, Volk T, Meiser A.

Anaesthesia. 2014 Nov;69(11):1241-50. doi: 10.1111/anae.12798. Epub 2014 Jul 9.

35.

Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.

Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Michl M, Heinemann V, Stieber P, Schulz C.

Tumour Biol. 2014 Oct;35(10):10237-48. doi: 10.1007/s13277-014-2338-6. Epub 2014 Jul 17.

PMID:
25027407
36.

Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.

Mack F, Schäfer N, Kebir S, Stuplich M, Schaub C, Niessen M, Scheffler B, Herrlinger U, Glas M.

Oncology. 2014;86(5-6):369-72. doi: 10.1159/000360295. Epub 2014 Jun 18.

PMID:
24942787
37.

The Danube so colourful: a potpourri of plastic litter outnumbers fish larvae in Europe's second largest river.

Lechner A, Keckeis H, Lumesberger-Loisl F, Zens B, Krusch R, Tritthart M, Glas M, Schludermann E.

Environ Pollut. 2014 May;188:177-81. doi: 10.1016/j.envpol.2014.02.006. Epub 2014 Mar 4.

38.

Bevacizumab treatment in malignant meningioma with additional radiation necrosis. An MRI diffusion and perfusion case study.

Boström JP, Seifert M, Greschus S, Schäfer N, Glas M, Lammering G, Herrlinger U.

Strahlenther Onkol. 2014 Apr;190(4):416-21. doi: 10.1007/s00066-013-0505-0. Epub 2014 Jan 17.

PMID:
24429478
39.

Melatonin receptors mediate improvements of survival in a model of polymicrobial sepsis.

Fink T, Glas M, Wolf A, Kleber A, Reus E, Wolff M, Kiefer D, Wolf B, Rensing H, Volk T, Mathes AM.

Crit Care Med. 2014 Jan;42(1):e22-31. doi: 10.1097/CCM.0b013e3182a63e2b.

PMID:
24145838
40.

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.

Oncology. 2013;85(3):191-5. doi: 10.1159/000354692. Epub 2013 Sep 5.

PMID:
24008924
41.

Anticancer effects of niclosamide in human glioblastoma.

Wieland A, Trageser D, Gogolok S, Reinartz R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, Waha A, Koch P, Fimmers R, Pietsch T, Yachnis AT, Pincus DW, Steindler DA, Brüstle O, Simon M, Glas M, Scheffler B.

Clin Cancer Res. 2013 Aug 1;19(15):4124-36. doi: 10.1158/1078-0432.CCR-12-2895.

42.

Fine-mapping the contact sites of the Escherichia coli cell division proteins FtsB and FtsL on the FtsQ protein.

van den Berg van Saparoea HB, Glas M, Vernooij IG, Bitter W, den Blaauwen T, Luirink J.

J Biol Chem. 2013 Aug 23;288(34):24340-50. doi: 10.1074/jbc.M113.485888. Epub 2013 Jul 11.

43.

[Introduction into "Point-of-Care" testing: indications and limitations].

Glas M, Mauer D, Brün K, Volk T, Kreuer S.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2013 May;48(5):324-34. doi: 10.1055/s-0033-1347157. Epub 2013 Jun 12. German.

PMID:
23761030
44.

Vemurafenib for leptomeningeal melanomatosis.

Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M.

J Clin Oncol. 2013 Apr 10;31(11):e173-4. doi: 10.1200/JCO.2012.46.5773. Epub 2013 Mar 4. No abstract available.

PMID:
23460716
45.

Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.

Glas M, Coch C, Trageser D, Dassler J, Simon M, Koch P, Mertens J, Quandel T, Gorris R, Reinartz R, Wieland A, Von Lehe M, Pusch A, Roy K, Schlee M, Neumann H, Fimmers R, Herrlinger U, Brüstle O, Hartmann G, Besch R, Scheffler B.

Stem Cells. 2013 Jun;31(6):1064-74. doi: 10.1002/stem.1350.

46.

Intravascular CNS lymphoma: Successful therapy using high-dose methotrexate-based polychemotherapy.

Kebir S, Kuchelmeister K, Niehusmann P, Nelles M, Kim Y, Thanendrarajan S, Schäfer N, Stuplich M, Mack F, Scheffler B, Urbach H, Glas M, Herrlinger U.

Exp Hematol Oncol. 2012 Dec 5;1(1):37. doi: 10.1186/2162-3619-1-37.

47.

The O2, pH and Ca2+ microenvironment of benthic foraminifera in a high CO2 world.

Glas MS, Fabricius KE, de Beer D, Uthicke S.

PLoS One. 2012;7(11):e50010. doi: 10.1371/journal.pone.0050010. Epub 2012 Nov 15.

48.

Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands.

Wijtmans M, Scholten DJ, Roumen L, Canals M, Custers H, Glas M, Vreeker MC, de Kanter FJ, de Graaf C, Smit MJ, de Esch IJ, Leurs R.

J Med Chem. 2012 Dec 13;55(23):10572-83. doi: 10.1021/jm301240t. Epub 2012 Nov 14.

PMID:
23150943
49.

Primary CNS lymphoma: a clinician's guide.

Schäfer N, Glas M, Herrlinger U.

Expert Rev Neurother. 2012 Oct;12(10):1197-206. doi: 10.1586/ern.12.120. Review.

PMID:
23082736
50.

Sample transport by pneumatic tube system alters results of multiple electrode aggregometry but not rotational thromboelastometry.

Glas M, Mauer D, Kassas H, Volk T, Kreuer S.

Platelets. 2013;24(6):454-61. doi: 10.3109/09537104.2012.718383. Epub 2012 Aug 29.

PMID:
22931353

Supplemental Content

Support Center